Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the PVP protocol, combining Peptichemio, vincristine, and 6-methylprednisolone, resulted in remission for diffuse non-Hodgkin's lymphomas with moderate side effects.

This case report suggests that scalp arteriovenous malformations can cause local hair loss, which may recover following ethanol embolization treatment.

This study found that 95% of untreated advanced-stage follicular lymphoma patients responded to a single course of the Bexxar regimen, with 75% achieving complete remission and remaining disease-free for years.

In this case report, a nine-year-old child with vitiligo and alopecia areata was successfully treated with upadacitinib and UVB, resulting in a significant reduction in the affected areas, suggesting a promising treatment approach for similar pediatric cases.

Men with Addison disease should be screened for X-linked adrenoleukodystrophy if they have hair loss.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

This case report shares that a 25-year-old man with cerebral arteriovenous malformation was successfully treated with stereotactic radiosurgery in Bangladesh, achieving complete obliteration of the AVM without significant clinical symptoms.

This study reported that using UVB preirradiation and anti-CD154 antibody treatment in a humanized mouse model prolonged hair follicle allograft survival and reduced immune cell infiltration without needing generalized immunosuppression.

This study reports the first successful use of zanubrutinib to treat a 15-year-old Chinese girl with severe refractory Evans' syndrome, resulting in a sustained recovery of platelet counts and haemoglobin levels.

This study found that combining hair transplantation with platelet-rich plasma treatment significantly improved hair regeneration, reduced hair loss, and minimized skin lesion areas in patients with androgenic alopecia compared to hair transplantation alone, suggesting enhanced treatment efficacy.

In this study, chemotherapy-induced adverse drug reactions were common in cancer patients, highlighting the need for better pharmacovigilance and personalized treatment strategies to reduce their occurrence and severity.

In an outpatient cardiology center, this study found that introducing the AHA/ACC ABI screening protocol significantly increased the frequency of ABI ordering by 31.6% for symptomatic patients.

This study suggests that the combination of bendamustine and rituximab is at least as effective and possibly offers a better therapeutic index than other standard regimens as first-line treatment for certain lymphoma patients.

In this study, eight patients with hereditary vitamin D-resistant rickets who share a specific VDR mutation showed improved clinical symptoms except alopecia after up to 11 years of treatment.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

This study reports that newly diagnosed patients with Bachmann-Bupp syndrome exhibit a broader phenotype than previously documented, including late-onset seizures, and suggests a possible universal biochemical mechanism involving elevated ODC activity.

This study found that CMV infection in a mouse model of allogeneic transplantation was associated with increased allo-reactive T cell expansion and exacerbated graft-versus-host disease, highlighting the need for effective GvHD prophylaxis and treatment.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

Abatacept may help some people with alopecia areata regrow hair.

In this study, a 33-year-old HIV-infected man experienced alopecia areata after beginning zidovudine therapy, which reversed upon discontinuation.

This article discusses the development of non-myeloablative stem cell transplants, which may expand the safe treatment range of allogeneic SCT, but presents no new clinical results.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

This analysis reports that hepatitis B surface protein antigen exposure is associated with an increased risk of alopecia areata.

This study identified two distinct histological patterns in permanent alopecia following bone marrow transplantation, suggesting links to myeloablative chemotherapy and chronic graft-versus-host disease.

In this study, combining thalidomide with CHOP treatment showed a significantly higher effective rate in treating peripheral T-cell lymphoma compared to CHOP alone, while both regimens were associated with similar levels of adverse reactions.

This study found that VMAT hair-sparing WBRT partially preserved scalp hair at four weeks post-treatment without compromising symptomatic disease control in the short term, but reduced hair loss did not improve quality of life.

A man developed alopecia areata after starting cancer treatment with vandetanib.

This study found that topical immunotherapy affects angiogenesis and immune cell ratios in the scalp, potentially offering insights into the mechanisms underlying alopecia areata.

Acyclovir can prevent rejection of skin grafts in herpes-related lip leucoderma.